Agios Pharmaceuticals reported $1.06M in Loan Capital for its fiscal quarter ending in September of 2022.





Loan Capital Change Date
AbbVie USD 62.48B 2.05B Jun/2026
Agios Pharmaceuticals USD 1.06M 0 Sep/2022
Alnylam Pharmaceuticals USD 2.11B 358.58M Sep/2026
Amgen USD 51.61B 250M Sep/2026
Arrowhead Research USD 824.07M 401.34M Jun/2026
Astellas Pharma JPY 270B 50B Sep/2026
AstraZeneca USD 28.8B 2.79B Sep/2026
Bayer EUR 37.7B 6.54B Sep/2026
Biogen USD 7.29B 1.7M Sep/2026
BioMarin Pharmaceutical USD 3.51B 12.96M Sep/2026
Bristol-Myers Squibb USD 41.85B 244M Sep/2026
Daiichi Sankyo JPY 499.93B 75M Sep/2026
Eli Lilly USD 46.99B 872M Sep/2026
Gilead Sciences USD 23.82B 17M Sep/2026
GlaxoSmithKline GBP 21.7B 7.75B Sep/2026
Incyte USD 28.42M 994K Jun/2026
Ionis Pharmaceuticals USD 1.77B 140.62M Sep/2026
Merck USD 49.69B 1.39B Sep/2026
Moderna USD 3.55B 2.95B Sep/2026
Nektar Therapeutics USD 60.27M 2.89M Mar/2026
Novartis USD 38.38B 893M Sep/2026
Novartis USD 36.7B 748M Sep/2026
Pfizer USD 60B 498M Sep/2026
Puma Biotechnology USD 10.87M 222K Jun/2025
Regeneron Pharmaceuticals USD 1.99B 400K Sep/2026
Roche Holding CHF 25.22B 2.21B Jun/2026
Sarepta Therapeutics USD 699.39M 148.23M Sep/2026
Vertex Pharmaceuticals USD 3.5B 3.39B Sep/2026